Wird geladen...
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is highly selective for EGFR-activating mutations as well as the EGFR T790M mutation in patients with advanced non-small cell lung cancer (NSCLC) with EGFR oncogene addiction. Desp...
Gespeichert in:
| Veröffentlicht in: | Br J Cancer |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Nature Publishing Group UK
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6889286/ https://ncbi.nlm.nih.gov/pubmed/31564718 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0573-8 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|